Catalyst Pharmaceutical CPRX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's stock-based comp?
- Catalyst Pharmaceutical (CPRX) reported stock-based comp of $6.26M in Q1 2026.
- How has Catalyst Pharmaceutical's stock-based comp changed year-over-year?
- Catalyst Pharmaceutical's stock-based comp increased by 7.0% year-over-year, from $5.85M to $6.26M.
- What is the long-term trend for Catalyst Pharmaceutical's stock-based comp?
- Over 4 years (2021 to 2025), Catalyst Pharmaceutical's stock-based comp has grown at a 42.1% compound annual growth rate (CAGR), from $6.07M to $24.78M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.